Welcome to our dedicated page for AbbVie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AbbVie Inc. filings document formal disclosures for a global pharmaceutical issuer with common stock and multiple senior note series registered on the New York Stock Exchange. Recent Form 8-K reports cover quarterly and annual results, preliminary earnings impacts from acquired IPR&D and milestone expenses, material-event disclosures, material agreements and capital-structure updates.
The company’s filing record also includes debt-financing disclosures for completed senior note offerings and definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items. These documents provide regulatory detail on AbbVie’s operating results, listed securities, governance framework and financing activity.
MEYER MELODY B reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Melody B. Meyer received an award of 1,118 shares of common stock in the form of restricted stock units. These units were granted at no cash cost to her and increase her directly owned holdings to 17,616 shares.
The restricted stock units were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program and will be settled on a one-to-one basis in AbbVie common stock upon the earlier of her separation from service, death, or a change in control as defined in the program.
Hart Brett J reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Brett J. Hart received an award of 1,118 shares of common stock in the form of restricted stock units. These units were granted at no cash cost to him and increase his direct holdings to 20,590 shares after the award.
The restricted stock units were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program and will be settled one-for-one in AbbVie common stock. Settlement will occur on the earlier of his separation from service, death, or a change in control as defined in the program.
FREYMAN THOMAS C reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Thomas C. Freyman received a grant of 1,118 restricted stock units of AbbVie common stock at a stated price of $0.00 per share. After this award, he directly holds 127,869 shares of AbbVie common stock.
The restricted stock units were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program and will be paid one-for-one in AbbVie shares upon the earlier of his separation from service, death, or a defined change in control. Additional AbbVie shares are held in trusts for his spouse and son, totaling 1,941 shares and 4,000 shares respectively, for which he disclaims beneficial ownership.
AbbVie Inc. director Jennifer L. Davis received an equity-based compensation award rather than buying shares on the market. She was granted 1,118 restricted stock units under AbbVie’s Amended and Restated 2013 Incentive Stock Program, increasing her reported direct holdings to 3,643 common shares. These units will convert into AbbVie stock on a one-to-one basis upon her separation from service, death, or a qualifying change in control, aligning her compensation more closely with long-term shareholder value.
BURNSIDE WILLIAM H.L. reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director William H.L. Burnside received a grant of 1,118 restricted stock units under the AbbVie Amended and Restated 2013 Incentive Stock Program. These units will be settled one-for-one in AbbVie common stock upon the earlier of separation from service, death, or a change in control, bringing his reported holdings to 28,076 shares.
AbbVie Inc. director Roxanne S. Austin received an award of 1,118 shares of common stock as a grant under the AbbVie Amended and Restated 2013 Incentive Stock Program. Following this compensation-related acquisition, she beneficially owns 39,576 AbbVie common shares directly.
According to the award terms, these are restricted stock units that will be paid on a one-to-one basis in AbbVie common shares upon the earlier of her separation from service, death, or a change in control as defined in the program.
AbbVie reported first‑quarter 2026 results with solid revenue growth but lower earnings. Net revenues rose to $15.0 billion, up 12% year over year, driven by strong expansion of immunology drugs Skyrizi and Rinvoq, neuroscience brands like Vraylar, Botox Therapeutic, Ubrelvy and Qulipta, and aesthetics products including Botox Cosmetic.
Operating earnings increased to $4.0 billion, but net earnings attributable to AbbVie fell to $695 million and diluted EPS to $0.39, mainly due to a $2.4 billion non‑cash increase in contingent consideration liabilities and $744 million of acquired R&D and milestone expense, including a $650 million upfront payment to RemeGen.
AbbVie generated strong operating cash flow of $3.8 billion, raised $8.0 billion through new senior notes, paid $3.1 billion in dividends and repurchased $1.1 billion of stock. The company highlighted a large late‑stage pipeline, new regulatory filings for Skyrizi and Rinvoq, and a voluntary U.S. pricing agreement alongside major planned U.S. manufacturing investments.
AbbVie Inc ownership filing: Vanguard Capital Management reports 132,924,058 shares of Common Stock, representing 7.51% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 132,924,058 shares and sole voting power for 18,043,734 shares. The disclosure notes these holdings include securities held for Vanguard funds and managed accounts and identifies affiliated business units that exercise voting or dispositive power on behalf of clients.
AbbVie reported strong first-quarter 2026 results, with worldwide net revenues of $15.002 billion, up 12.4% year over year on a reported basis (10.3% operational). Growth was driven by immunology and neuroscience, while oncology was flat and aesthetics grew modestly.
Immunology net revenues were $7.290 billion, up 16.4%, led by Skyrizi at $4.483 billion and Rinvoq at $2.119 billion, which more than offset a 38.6% decline in Humira to $688 million. Neuroscience net revenues rose 26.0% to $2.875 billion, with Botox Therapeutic at $1.009 billion and combined Ubrelvy/Qulipta at $635 million.
On a GAAP basis, diluted EPS was $0.39, down 45.8%, while adjusted diluted EPS rose 7.7% to $2.65, including an unfavorable $0.41 per-share impact from acquired IPR&D and milestones expense. AbbVie raised its full-year 2026 adjusted EPS guidance to a range of $14.08–$14.28.
AbbVie Inc. updated its 2026 earnings guidance to reflect a sizeable first-quarter charge for acquired in-process R&D and milestones. The company expects to record $744 million of pre-tax acquired IPR&D and milestones expense in the first quarter of 2026, which is estimated to reduce both GAAP and adjusted diluted earnings per share by $0.41.
Including this impact, AbbVie now guides full-year 2026 adjusted diluted EPS to a range of $13.96 to $14.16, compared with prior guidance that excluded this expense. First-quarter 2026 adjusted diluted EPS guidance, including the charge, is $2.56 to $2.60, down from the previously announced range of $2.97 to $3.01 that did not include the IPR&D and milestones expense.